Dec 1, 2009
By:
Ron Feemster
Our sixth annual pipeline report details 44 drugs that industry will be talking about in 2010.
|
|
Sep 1, 2009
By:
Ron Feemster
The obesity pipeline, despite a hugely underserved market potentially worth $11 billion, is awfully thin.
|
Dec 1, 2008
By:
Ron Feemster
We scrub industry's pipeline to find the drugs that everyone will be talking about in 2009 and beyond
|
Aug 2, 2006
By:
Ron Feemster
Pfizer's new CEO shares his views on a range of hot topics, from sales and marketing to regulation, compliance, and corporate culture.
|
Pfizer was an early adopter of RFID, but CEO Hank McKinnell says a mature track-and-trace system is five years down the road.
Jul 1, 2006
By:
Ron Feemster
RFID is not ready for prime time anywhere. Certainly not in the US. There is no way RFID gives you end-to-end control of the product.
|
In a new book, a pharma executive recalls what he learned behind the counter of a family Dairy Queen
Jul 1, 2006
By:
Ron Feemster
At first glance, you might think Bob Miglani comes from a pharma family. He and both of his younger sisters began their careers as sales reps after college. But behind their success in big business lie formative experiences at the Dairy Queen stores owned by their uncle and parents, who are immigrants from India. Even today, Miglani, whose fulltime job is in Pfizer's public affairs department, spends some weekends serving cones at the family business. In his new book, Treat Your Customers: Thirty Lessons on Service and Sales That I Learned at My Family's Dairy Queen Store (Hyperion, 2006), Miglani, 36, shares the core values that work in small business and corporate America.
|
|
Law the Pfizer way: Jeffrey Kindler cracks down on counterfeiters, builds a private police force, and makes nice with OIG. Then he hires a foreign-policy expert.
Jul 1, 2006
By:
Ron Feemster
Jeffrey Kindler holds two blue, diamond-shaped pills in the palm of his hand. One is authentic Viagra, manufactured by Pfizer. The other is counterfeit, maybe bought by an undercover Pfizer investigator, or intercepted when smugglers crossed a border, or perhaps seized in a raid on an illegal Chinese factory. Kindler challenges visitors and fellow employees to tell the difference between the two pills. Neither looks in any obvious way "fake," and no one among the journalists, corporate communications employees, or even security specialists gathered in Pfizer's global security operations center cares to hazard a guess.
|
May 10, 2006
By:
Ron Feemster
How can FDA track billions of prescription drugs from manufacturer
to patient? Paul Chang, leader of IBM?s RFID program, imagines a
thin database in the sky.
|
A New Jersey Teamsters local says Pfizer tricked them into paying for off-label Lipitor prescriptions. Do you have any questions about that? We do.
May 1, 2006
By:
Ron Feemster
The world's largest drug manufacturer must answer off-label promotion charges brought by a new adversary. Not FDA, with its warning letters and threats of marketing sanctions, and not the Office of the Inspector General (OIG) at Health and Human Services, which often sues for fraud, forces huge settlements, and requires companies to do business under restrictive corporate integrity agreements. Instead, the company faces a class-action civil suit from insurance companies and union welfare funds, groups that, until recently, Pfizer regarded primarily as customers—or at least people who picked up the tab for customers. Now, led by the Welfare Fund of a Teamsters local from New Jersey, third-party payers are suing under RICO, the Racketeering Influenced and Corrupt Organizations Act. If their suit is successful, payers who have covered billions of dollars worth of Lipitor (atorvastatin) over the past five years will receive treble damages for the cost of off-label prescriptions. The suit may also attract..
|
|
PharmExec Blog
Follow Us
RSS
Bookstore
